|
|
| | (2-Chloro-7H-purin-6-yl)-furan-2-ylmethyl-amine Basic information |
| Product Name: | (2-Chloro-7H-purin-6-yl)-furan-2-ylmethyl-amine | | Synonyms: | (2-Chloro-7H-purin-6-yl)-furan-2-ylmethyl-amine;2-Chloro-N-(furan-2-ylmethyl)-9H-purin-6-amine;2-Chloro-N6-furfuryladenine;9H-Purin-6-amine, 2-chloro-N-(2-furanylmethyl)-;(2-Chloro-7H-purin-6-yl)furan-2-ylmethanamine;(2-chloro-7H-purine-6-yl)furan-2-methylamine | | CAS: | 101862-47-9 | | MF: | C10H8ClN5O | | MW: | 249.66 | | EINECS: | | | Product Categories: | | | Mol File: | 101862-47-9.mol |  |
| | (2-Chloro-7H-purin-6-yl)-furan-2-ylmethyl-amine Chemical Properties |
| Melting point | 241-242 °C | | Boiling point | 388.3±52.0 °C(Predicted) | | density | 1.69±0.1 g/cm3(Predicted) | | storage temp. | 4°C, protect from light | | solubility | DMSO:24.97(Max Conc. mg/mL);100.0(Max Conc. mM) | | form | Solid | | pka | 6.99±0.20(Predicted) | | color | White to Off-White | | InChI | 1S/C10H8ClN5O/c11-10-15-8(7-9(16-10)14-5-13-7)12-4-6-2-1-3-17-6/h1-3,5H,4H2,(H2,12,13,14,15,16) | | InChIKey | QGUOPVCOXHVPJX-UHFFFAOYSA-N | | SMILES | Clc1nc2[nH]cnc2c(n1)NCc3[o]ccc3 |
| WGK Germany | WGK 3 | | Storage Class | 6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | | Hazard Classifications | Acute Tox. 3 Oral |
| | (2-Chloro-7H-purin-6-yl)-furan-2-ylmethyl-amine Usage And Synthesis |
| Uses | 2-Chloro-N-[(furan-2-yl)methyl]-7H-purin-6-amine is a chlorinated Kinetin (K570005) which is a cell division factor found in various plant parts and in yeast. 2-Chloro-N-[(furan-2-yl)methyl]-7H-purin-6-amine is used in the synthesis of zinc and copper complexes. | | Biological Activity | Orally active, CDC2-like kinase 1 (CLK1) allosteric activator th at enhances promotes CLK1/SRSF5 pathway-mediated pre-mRNA splicing events.
RECTAS is an orally active, CDC2-like kinase 1 (CLK1) allosteric activator th at enhances SRSF6 c-terminal RS domain phosphorylation by CLK1, thereby promoting CLK1/SRSF5 pathway-mediated pre-mRNA splicing events. RECTAS restores IKBKAP-familial dysautonomia (FD) exon 20 inclusion in cultured cells (2-10 μM; FD patient iPSC-SNs & murine neuro 2A cells) and in IKBKAP-FD transgenic mice in vivo (two p.o. doses of 300 or 400 mg/kg 4h apart). RECTAS suppresses MC38 tumor growth (by 37/47% at 10/25 μM at the end of 33-day treatment via daily intratumoral injection) by reducing aberrant splicing events and enhancing the splice-neoantigens production. | | storage | Store at -20°C |
| | (2-Chloro-7H-purin-6-yl)-furan-2-ylmethyl-amine Preparation Products And Raw materials |
|